J. Goldman & CO LP Biogen Inc. Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
A detailed history of J. Goldman & CO LP transactions in Biogen Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 40,000 shares of BIIB stock, worth $6.95 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
40,000
Previous 20,000
100.0%
Holding current value
$6.95 Million
Previous $4.31 Million
115.03%
% of portfolio
0.28%
Previous 0.15%
Shares
7 transactions
Others Institutions Holding BIIB
# of Institutions
1,018Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$2.88 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.84 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.53 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.23 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$987 Million0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $25B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...